Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 447

2.

Recent advances in the development of oncolytic HSV-1 vectors: 'arming' of HSV-1 vectors and application of bacterial artificial chromosome technology for their construction.

Jeyaretna DS, Kuroda T.

Curr Opin Mol Ther. 2007 Oct;9(5):447-66. Review. Erratum in: Curr Opin Mol Ther. 2007 Dec;9(6):611.

PMID:
17932809
4.

Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models.

Terada K, Wakimoto H, Tyminski E, Chiocca EA, Saeki Y.

Gene Ther. 2006 Apr;13(8):705-14.

PMID:
16421599
6.

Oncolytic virus therapy using genetically engineered herpes simplex viruses.

Todo T.

Front Biosci. 2008 Jan 1;13:2060-4. Review.

PMID:
17981691
8.

Coupling generation of cytomegalovirus deletion mutants and amplification of viral BAC clones.

Wang W, Patterson CE, Yang S, Zhu H.

J Virol Methods. 2004 Nov;121(2):137-43.

PMID:
15381350
9.

Establishment of a novel foreign gene delivery system combining an HSV amplicon with an attenuated replication-competent virus, HSV-1 HF10.

Zhang L, Daikoku T, Ohtake K, Ohtsuka J, Nawa A, Kudoh A, Iwahori S, Isomura H, Nishiyama Y, Tsurumi T.

J Virol Methods. 2006 Nov;137(2):177-83. Epub 2006 Jul 18.

PMID:
16854473
10.

A rapid method for targeted modification and screening of recombinant bacterial artificial chromosome.

Misulovin Z, Yang XW, Yu W, Heintz N, Meffre E.

J Immunol Methods. 2001 Nov 1;257(1-2):99-105.

PMID:
11687243
11.

[Generation of a series of recombinant herpes simplex viruses which can provide replicating and packaging functions for recombinant adeno-associated virus].

Wu Z, Wu X, Hou Y.

Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2002 Mar;16(1):74-8. Chinese.

PMID:
11986753
12.

Oncolytic herpes simplex virus engineering and preparation.

Agarwalla PK, Aghi MK.

Methods Mol Biol. 2012;797:1-19. doi: 10.1007/978-1-61779-340-0_1. Review.

PMID:
21948465
13.

Oncolytic recombinant herpes simplex virus for treatment of orthotopic liver tumors in nude mice.

Chung YS, Miyatake S, Miyamoto A, Miyamoto Y, Dohi T, Tanigawa N.

Int J Oncol. 2006 Apr;28(4):793-8.

PMID:
16525626
14.

Intraperitoneal oncolytic and tumor vaccination therapy with replication-competent recombinant virus: the herpes paradigm.

Coukos G, Courreges MC, Benencia F.

Curr Gene Ther. 2003 Apr;3(2):113-25. Review.

PMID:
12653405
15.

Engineering cell lines for production of replication defective HSV-1 gene therapy vectors.

Grant KG, Krisky DM, Ataai MM, Glorioso JC 3rd.

Biotechnol Bioeng. 2009 Mar 1;102(4):1087-97. doi: 10.1002/bit.22123.

PMID:
18828174
16.

Mini-lambda: a tractable system for chromosome and BAC engineering.

Court DL, Swaminathan S, Yu D, Wilson H, Baker T, Bubunenko M, Sawitzke J, Sharan SK.

Gene. 2003 Oct 2;315:63-9.

PMID:
14557065
17.

Oncolytic herpes virus with defective ICP6 specifically replicates in quiescent cells with homozygous genetic mutations in p16.

Aghi M, Visted T, Depinho RA, Chiocca EA.

Oncogene. 2008 Jul 10;27(30):4249-54. doi: 10.1038/onc.2008.53. Epub 2008 Mar 17.

PMID:
18345032
18.

A highly efficient Escherichia coli-based chromosome engineering system adapted for recombinogenic targeting and subcloning of BAC DNA.

Lee EC, Yu D, Martinez de Velasco J, Tessarollo L, Swing DA, Court DL, Jenkins NA, Copeland NG.

Genomics. 2001 Apr 1;73(1):56-65.

PMID:
11352566
19.

Tumor-specific activity of cellular regulatory elements is down-regulated upon insertion into the herpes simplex virus genome.

Glass M, Söling A, Messerle M.

J Neurovirol. 2008 Nov;14(6):522-35. doi: 10.1080/13550280802348214.

PMID:
18979278

Supplemental Content

Support Center